S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Better Than Oil Stocks (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
It's Called "the Singularity" (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
It's Called "the Singularity" (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Better Than Oil Stocks (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
It's Called "the Singularity" (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
It's Called "the Singularity" (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Better Than Oil Stocks (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
It's Called "the Singularity" (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
It's Called "the Singularity" (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Better Than Oil Stocks (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
It's Called "the Singularity" (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
It's Called "the Singularity" (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
NASDAQ:KPTI

Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis

$1.24
+0.11 (+9.73%)
(As of 02/23/2024 08:53 PM ET)
Today's Range
$1.10
$1.31
50-Day Range
$0.72
$1.66
52-Week Range
$0.62
$4.87
Volume
1.54 million shs
Average Volume
2.04 million shs
Market Capitalization
$142.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Karyopharm Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
383.9% Upside
$6.00 Price Target
Short Interest
Bearish
16.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
-0.01mentions of Karyopharm Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$27,076 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.15) to ($1.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.68 out of 5 stars

Medical Sector

258th out of 936 stocks

Pharmaceutical Preparations Industry

115th out of 422 stocks


KPTI stock logo

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

KPTI Stock Price History

KPTI Stock News Headlines

KPTI Mar 2024 1.500 call
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Karyopharm Therapeutics Inc (KPTI)
Karyopharm Therapeutics Inc KPTI
See More Headlines
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
2/25/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KPTI
Fax
N/A
Employees
385
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$10.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+383.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-165,290,000.00
Pretax Margin
-95.64%

Debt

Sales & Book Value

Annual Sales
$157.07 million
Book Value
($0.15) per share

Miscellaneous

Free Float
110,731,000
Market Cap
$142.02 million
Optionable
Optionable
Beta
-0.19
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Richard A. Paulson M.B.A. (Age 57)
    President, CEO & Director
    Comp: $1.36M
  • Dr. Sharon Shacham M.B.A. (Age 54)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
    Comp: $1.4M
  • Mr. Michael P. Mason CPAMr. Michael P. Mason CPA (Age 49)
    M.B.A., Executive VP, CFO & Treasurer
    Comp: $681.59k
  • Mr. Michael J. Mano J.D. (Age 47)
    Senior VP, General Counsel & Secretary
    Comp: $625.08k
  • Ms. Sohanya Cheng M.B.A. (Age 41)
    Executive VP & Chief Commercial Officer
    Comp: $664.3k
  • Mr. Stuart Poulton
    Executive VP & Chief Development Officer
  • Dr. Mansoor Raza Mirza M.D. (Age 63)
    Clinical Consultant, Member of Scientific Advisory Board & Independent Director
    Comp: $150k
  • Mr. Cameron Peters (Age 64)
    Vice President of Finance, Assistant Treasurer & Principal Accounting Officer
  • Ms. Elhan Webb C.F.A.
    Senior Vice President of Investor Relations
  • Mr. James Accumanno J.D.
    Chief Compliance Officer














KPTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KPTI shares.
View KPTI analyst ratings
or view top-rated stocks.

What is Karyopharm Therapeutics' stock price target for 2024?

5 equities research analysts have issued twelve-month target prices for Karyopharm Therapeutics' shares. Their KPTI share price targets range from $3.00 to $10.00. On average, they predict the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 383.9% from the stock's current price.
View analysts price targets for KPTI
or view top-rated stocks among Wall Street analysts.

How have KPTI shares performed in 2024?

Karyopharm Therapeutics' stock was trading at $0.8650 at the start of the year. Since then, KPTI stock has increased by 43.4% and is now trading at $1.24.
View the best growth stocks for 2024 here
.

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our KPTI earnings forecast
.

How can I listen to Karyopharm Therapeutics' earnings call?

Karyopharm Therapeutics will be holding an earnings conference call on Thursday, February 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.01. The business had revenue of $37.69 million for the quarter, compared to analyst estimates of $25.84 million. During the same quarter in the prior year, the company earned ($0.73) earnings per share.

What ETF holds Karyopharm Therapeutics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio.

What guidance has Karyopharm Therapeutics issued on next quarter's earnings?

Karyopharm Therapeutics issued an update on its FY 2023 earnings guidance on Monday, January, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $146.0 million-$146.0 million, compared to the consensus revenue estimate of $150.0 million.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.61%), Palo Alto Investors LP (4.45%), GSA Capital Partners LLP (2.04%), BNP Paribas Financial Markets (1.54%), Goldman Sachs Group Inc. (1.13%) and Northern Trust Corp (0.87%). Insiders that own company stock include Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Stuart Poulton.
View institutional ownership trends
.

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KPTI) was last updated on 2/26/2024 by MarketBeat.com Staff